Products

Solid Tumor Testing Minimal Residual Disease Testing Hematologic Malignancies Testing RUO/IUO: Multi-omics Detection Early Cancer Detection
Services

Pharma Biomarker and CDx Services IVD Channel Partner Development Sequencing Services Early Cancer Detection Services

中文 EN

Luvometinib in patients with Langerhans cell histiocytosis, Erdheim–Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study

Release date：October 11, 2025

Announcer：Burning Rock

Previous: ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma

Recommended News

November 22, 7646

ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma

September 03, 2025

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study

May 21, 2025

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

November 22, 7219

Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring

Contact Our Experts

We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."